OPPORTUNISTIC MYCOSES Sevtap Arikan MD OPPORTUNISTIC MYCOSES General

  • Slides: 28
Download presentation
OPPORTUNISTIC MYCOSES Sevtap Arikan, MD

OPPORTUNISTIC MYCOSES Sevtap Arikan, MD

OPPORTUNISTIC MYCOSES General features CAUSATIVE AGENTS Saprophyte in nature/found in normal flora HOST Immunosupressed

OPPORTUNISTIC MYCOSES General features CAUSATIVE AGENTS Saprophyte in nature/found in normal flora HOST Immunosupressed /other risk factors

OPPORTUNISTIC MYCOSES 4 Candidiasis 4 Cryptococcosis 4 Aspergillosis 4 Zygomycosis 4 Other: Trichosporonosis, fusariosis,

OPPORTUNISTIC MYCOSES 4 Candidiasis 4 Cryptococcosis 4 Aspergillosis 4 Zygomycosis 4 Other: Trichosporonosis, fusariosis, penicillosis…… ***ANY fungus found in nature may give rise to opportunistic mycoses ***

CANDIDIASIS 4 Most commonly encountered opportunistic mycoses worldwide 4 Cellular immunity protects against mucocutaneous

CANDIDIASIS 4 Most commonly encountered opportunistic mycoses worldwide 4 Cellular immunity protects against mucocutaneous candidiasis, neutrophiles protect against invasive candidiasis 4 Endogenous inf. 4 Etio: Candida spp. Most common: 1. C. albicans 2. C. tropicalis

MOST COMMONLY ISOLATED CANDIDA SPECIES 4 C. albicans 4 C. tropicalis 4 C. parapsilosis

MOST COMMONLY ISOLATED CANDIDA SPECIES 4 C. albicans 4 C. tropicalis 4 C. parapsilosis 4 C. kefyr 4 C. glabrata 4 C. krusei 4 C. guillermondii 4 C. lusitaniae

Candida MORPHOLOGICAL FEATURES 4 Micr. Budding yeast cells Pseudohyphae, true hyphae 4 Macr. Creamy

Candida MORPHOLOGICAL FEATURES 4 Micr. Budding yeast cells Pseudohyphae, true hyphae 4 Macr. Creamy yeast colonies (SDA) 4 Germ tube (C. albicans, C. dubliniensis) 4 Chlamydospore (C. albicans, C. dubliniensis) 4 Identification Germ tube, fermentation and assimilation reactions

Candida PATHOGENICITY 4 Attachment (Germ tube is more adhesive than yeast cell) 4 Adherence

Candida PATHOGENICITY 4 Attachment (Germ tube is more adhesive than yeast cell) 4 Adherence to plastic surfaces (catheter, prosthetic valve. . ) 4 Protease 4 Phospholipase

CANDIDIASIS Risk factors 4 Physiological. Pregnancy, elderly, infancy 4 Traumatic. Burn, infection 4 Hematological.

CANDIDIASIS Risk factors 4 Physiological. Pregnancy, elderly, infancy 4 Traumatic. Burn, infection 4 Hematological. Cellular immune deficiency, AIDS, chronic granulamatous disease, aplastic anemia, leukemia, lymphoma. . . 4 Endocrinological. DM, hypoparathyroidism, Addison disease 4 Iatrogenic. Oral contraceptives, antibiotics, steroid, chemotherapy, catheter. . .

CANDIDIASIS Clinical manifestations-I 1. CUTANEOUS and SUBCUTANEOUS 4 Oral 4 Vaginal 4 Onychomycosis 4

CANDIDIASIS Clinical manifestations-I 1. CUTANEOUS and SUBCUTANEOUS 4 Oral 4 Vaginal 4 Onychomycosis 4 Dermatitis 4 Diaper rash 4 Balanitis

CANDIDIASIS Clinical manifestations-II 2. SYSTEMIC 4 Peritonitis 4 Esophagitis 4 Hepatosplenic 4 Pulmonary inf.

CANDIDIASIS Clinical manifestations-II 2. SYSTEMIC 4 Peritonitis 4 Esophagitis 4 Hepatosplenic 4 Pulmonary inf. 4 Cystitis 4 Pyelonephritis 4 Endocarditis 4 Myocarditis 4 Endophthalmitis 4 Arthritis 4 Osteomyelitis 4 Menengitis 4 Skin lesions

4 CANDIDIASIS Clinical manifestations-III 3. CHRONIC MUCOCUTANEOUS 4 Candida inf. of skin and mucous

4 CANDIDIASIS Clinical manifestations-III 3. CHRONIC MUCOCUTANEOUS 4 Candida inf. of skin and mucous membranes 4 Verrucose lesions 4 Impaired cellular immunity 4 Autosomal recessive trait 4 Hypoparathyroidism, iron deficiency

CANDIDIASIS Diagnosis 4 Direct micr. ic examination Yeast cells, pseudohyphae, true hyphae 4 Culture

CANDIDIASIS Diagnosis 4 Direct micr. ic examination Yeast cells, pseudohyphae, true hyphae 4 Culture SDA, routine bacteriological media 4 Serology Detection of mannan antigen (ELISA, RIA, IF, latex agglutination)

CANDIDIASIS Treatment 4 CUTANEOUS Topical antifungal: Ketoconazole, miconazole, nystatin 4 SYSTEMIC Amphotericin B Fluconazole,

CANDIDIASIS Treatment 4 CUTANEOUS Topical antifungal: Ketoconazole, miconazole, nystatin 4 SYSTEMIC Amphotericin B Fluconazole, itraconazole 4 CHRONIC MUCOCUTANEOUS Amphotericin B Fluconazole, itraconazole Transfer factor

CRYPTOCOCCOSIS 4 Underlying cellular immunodeficiency (AIDS, lymphoma) 4 Exogenous inf. 4 Pathogenesis Inhalation of

CRYPTOCOCCOSIS 4 Underlying cellular immunodeficiency (AIDS, lymphoma) 4 Exogenous inf. 4 Pathogenesis Inhalation of yeasts 4 Etio. Cryptococcus neoformans

Cryptococcus neoformans General properties 4 Natural reservoir Soil, bird droppings 4 Micr. Encapsulated yeast

Cryptococcus neoformans General properties 4 Natural reservoir Soil, bird droppings 4 Micr. Encapsulated yeast (India ink) 4 Macr. Creamy, mucoid colonies (SDA) 4 Serotypes A-D (most frequently A) 4 Pathogenicity factors a. Capsule b. Diphenol oxidase (+) (Bird seed agar/ caffeic acid medium) c. Ability to grow at 37°C

CRYPTOCOCCOSIS Clinical manifestations 1. PULMONARY Asymptomatic/flu-like/hilar lap/cavitation 2. DISSEMINATED **Meningitis (acute/chronic) Cryptococcoma Skin lesions

CRYPTOCOCCOSIS Clinical manifestations 1. PULMONARY Asymptomatic/flu-like/hilar lap/cavitation 2. DISSEMINATED **Meningitis (acute/chronic) Cryptococcoma Skin lesions Other

CRYPTOCOCCOSIS Diagnosis 4 Samples CSF, sputum, aspiration from skin lesion 4 Direct exam. India

CRYPTOCOCCOSIS Diagnosis 4 Samples CSF, sputum, aspiration from skin lesion 4 Direct exam. India ink 4 Culture SDA 4 Serology*** Detection of capsule antigen in CSF and serum by latex agglutination test

CRYPTOCOCCOSIS Treatment 4 Amphotericin B (+ flucytosine) 4 Life-long fluconazole prophylaxis following primary treatment

CRYPTOCOCCOSIS Treatment 4 Amphotericin B (+ flucytosine) 4 Life-long fluconazole prophylaxis following primary treatment (in AIDS patients)

ASPERGILLOSIS Etio: Aspergillus spp. (most common: A. fumigatus) Risc factors and pathogenesis 1. Immunosupression,

ASPERGILLOSIS Etio: Aspergillus spp. (most common: A. fumigatus) Risc factors and pathogenesis 1. Immunosupression, DM. . exogenous inf. (inhalation of spores) 2. Inhalation of spores by atopic host Hypersensitivity reactions (allergy) 3. Ingestion of products contaminated with Aspergillus toxins Mycotoxicosis / hepatocellular and colon carcinoma

Aspergillus GENERAL FEATURES 4 Natural reservoir: air, soil 4 Pathogenicity factors: hypha, phospholipase 4

Aspergillus GENERAL FEATURES 4 Natural reservoir: air, soil 4 Pathogenicity factors: hypha, phospholipase 4 Infected tissue: vascular invasion, thrombus, infarct, bleeding 4 Macr: powdery mould colonies (color of the spores varies from one species to other) 4 Micr: septate hyphae (dichotomous branching), vesicule, phialides, microconidia

ASPERGILLOSIS Clinical manifestations-I I. ALLERGIC ASPERGILLOSIS 1. Asthma (Type I) 2. Allergic bronchopulmonary aspergillosis

ASPERGILLOSIS Clinical manifestations-I I. ALLERGIC ASPERGILLOSIS 1. Asthma (Type I) 2. Allergic bronchopulmonary aspergillosis (Types I, III) II. NONINVASIVE LOCAL COLONIZATION 1. Aspergilloma (Fungus ball) (lungs, paranasal sinuses) 2. Otomycosis (external otitis) 3. Onychomycosis 4. Eye inf. (conjunctival, corneal, intraocular)

ASPERGILLOSIS Clinical manifestations-II III. INVASIVE ASPERGILLOSIS 1. Pulmonary 2. Disseminated: GIT, brain, liver, kidney,

ASPERGILLOSIS Clinical manifestations-II III. INVASIVE ASPERGILLOSIS 1. Pulmonary 2. Disseminated: GIT, brain, liver, kidney, heart, skin, eye IV. MYCOTOXICOSIS

ASPERGILLOSIS Diagnosis 4 Samples Sputum, BAL, tissue. . . 4 Direct exam. Septate hyphae

ASPERGILLOSIS Diagnosis 4 Samples Sputum, BAL, tissue. . . 4 Direct exam. Septate hyphae and conidia in sputum; intravascular hyphae in tissue 4 Culture SDA (without cycloheximide) (should grow at least in 2 cultures !) 4 Serology Allergy (detection of specific Ig. E in serum-RAST) Invasive inf. (detection of galaktomannan antigen in serum--ELISA)

ASPERGILLOSIS Treatment 4 ALLERGIC Steroid 4 ASPERGILLOMA (if symptomatic) Surgery, amphotericin B 4 LOCAL,

ASPERGILLOSIS Treatment 4 ALLERGIC Steroid 4 ASPERGILLOMA (if symptomatic) Surgery, amphotericin B 4 LOCAL, SUPERFICIAL INF. Nystatin 4 INVASIVE INF. Surgical debridement Amphotericin B, itraconazole ***High mortality rate

ZYGOMYCOSIS 4 Causative agents Rhizopus, Rhizomucor, Mucor. . . 4 Natural reservoir Air, water,

ZYGOMYCOSIS 4 Causative agents Rhizopus, Rhizomucor, Mucor. . . 4 Natural reservoir Air, water, soil 4 Risk factors Diabetic ketoacidosis, immunosuppression 4 Pathogenesis Inhalation of sporangiospores 4 Infected tissue vascular invasion, thrombus, infarct, bleeding

ZYGOMYCOSIS Clinical manifestations I. RHINOCEREBRAL 4 Nose, paranasal sinuses, eye, brain and meninges are

ZYGOMYCOSIS Clinical manifestations I. RHINOCEREBRAL 4 Nose, paranasal sinuses, eye, brain and meninges are involved 4 Orbital cellulitis II. THORACIC 4 Pulmonary lesions, parenchymal necrosis III. LOCAL 4 Posttraumatic kidney inf. 4 Skin inf. following burn or surgery

ZYGOMYCOSIS Diagnosis 4 Samples Sputum, BAL, biopsy of paranasal sinuses. . 4 Direct exam.

ZYGOMYCOSIS Diagnosis 4 Samples Sputum, BAL, biopsy of paranasal sinuses. . 4 Direct exam. Nonseptate, ribbon-like hyphae which branch at right angles, sporangium 4 Culture SDA (cotton candy appearence)

ZYGOMYCOSIS Treatment 4 Surgical debridement 4 Amphotericin B ***High mortality rate

ZYGOMYCOSIS Treatment 4 Surgical debridement 4 Amphotericin B ***High mortality rate